No Data
CellSeed - temporarily reached the upper limit, with a rapid rise in Qualisys expanding interest in drug discovery-related stocks.
The stock reached a temporary high. Qualips <4894> announced its application for manufacturing and selling regenerative medicine products derived from iPS cell-derived cardiac muscle cell sheets, which has led to a surge in buying interest, reaching a stop-high buying indication, expanding into drug discovery-related stocks. Besides Cellseed, K Pharma <4896> and Heartseed <219A> are also rapidly rising. Cellseed disclosed the start of clinical trials for allogenic cartilage cell sheets on March 24, which seems to be attracting renewed buying interest.
Stock News Premium = The Growth Market will be (Delisted) for stocks with a Market Cap of less than 10 billion yen.
＜Currently, 70% of the stocks are affected, and the impact extends to IPOs＞ The Tokyo Stock Exchange has tightened the listing maintenance standards for the Growth Market and plans to delist companies that have not reached a Market Cap of 10 billion yen after five years of listing starting in 2030. Although there is still time until the deadline, 70% of the 612 listed stocks have a Market Cap of less than 10 billion yen, and the Emerging Markets, including IPOs, will enter a period of significant transformation. It has been noted that companies showcase impressive growth rates during their IPOs but deteriorate post-listing.
Express News | [Change Report] SBI Investment reports that the Shareholding percentage of Kepharma (4896.JP) has decreased to 15.1%.
Express News | [Change Report] SBI Investment reported a decrease in Shareholding of Kepharma (4896.JP) to 17.08%.
Express News | [Change Report] Itochu Technology Ventures reports a decrease in Shareholding of Keipharma (4896.JP) to 2.02%.
Kei Pharma - Extension of the joint research contract with Kitasato Institute regarding hearing disorders.
Kei Pharma <4896> announced on the 28th that it will extend its collaborative research contract with Kitasato Institute on hearing disorders until March 2026. The research group led by Professor Masato Fujioka from Kitasato University's School of Medicine, along with the company, has achieved certain results regarding the new efficacy of specific compounds in a hearing loss model using human iPS cell-derived inner ear cells. The extension of this collaborative research contract will allow for the acquisition of concrete data necessary for the implementation of corporate clinical trials and the start of the trials.
